Home > Oncology > WCLC 2018 > Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Updated overall survival (OS) data from the phase 3 PACIFIC trial have set a new standard of care for first-line treatment of unresectable stage 3 NSCLC. Previously reported results showed that durvalumab significantly improved progression-free survival (PFS) by 11.2 months compared with placebo (HR 0.52; 95% CI 0.42-0.65; P<0.001) [1]. The latest findings show a 2-year landmark survival rate of 66.3% for patients in the durvalumab group vs 55.6% in the placebo arm (P=0.005). Dr Scott Antonia (H. Lee Moffitt Cancer Center and Research Institute, USA) reported results at the live session [2]. The study was simultaneously published in the *New England Journal of Medicine* [3]. PACIFIC was a randomised, double-blind, placebo-controlled trial. A total of 709 patients with locally advanced, stage 3, unresectable NSCLC underwent concurrent chemoradiotherapy with no progression after treatment. Patients with any PD-L1 tumour status were enrolled into the study and randomised to receive...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on